secwatch.observer — SEC 8-K summary
======================================

Issuer:     Upstream Bio, Inc. (UPB)
CIK:        0002022626
Form:       8-K
Filed at:   2026-08-11T11:05:23+00:00
Accession:  0001193125-26-343407
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Upstream Bio Q2 net loss $39.7M; cash $261.3M funds through 2027; Phase 3 on track
--------------------------------------------------------------------------------

- Net loss of $39.7M for Q2 2026 vs $40.0M year ago; R&D spend $36.1M, G&A $7.1M.
- Cash and equivalents of $261.3M as of June 30, 2026, expected to fund operations through 2027.
- Phase 3 trials in severe asthma and CRSwNP on track to initiate Q1 2027; FDA End-of-Phase 2 meetings on schedule.
- Completed enrollment in Phase 2 VENTURE COPD trial (481 participants); data expected H2 2027.
- Phase 2 data: ~80% of verekitug-treated CRSwNP patients achieved NPS improvement; ERS late-breaking data Sept 5-9.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022626/000119312526343407/0001193125-26-343407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022626/000119312526343407/upb-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-343407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer